1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Gets US Injunction in Patent Infringement Case Against Adva Biotechnology

01/25/2022 | 10:51pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
COCOON HOLDINGS LIMITED 0.00% 0.32 Delayed Quote.6.67%
LONZA GROUP AG -2.97% 536.4 Delayed Quote.-27.42%
All news about LONZA GROUP AG
09:26aLonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
05/05LONZA GROUP AG : Proxy Statments
CO
04/29LONZA : to Divest its Quakertown Site Specialized in Particle Size Reduction; Business to ..
PU
04/29Investor group led by Derek Hennecke, TJ Higley, Mark Bamforth, Bill Mitchell and other..
CI
04/26Luzhu Biotech Develops Recombinant Herpes Zoster Vaccine and Bispecific Antibody using ..
AQ
04/25Lonza Joins Integral Molecular to Offer De-risking of Biotherapeutics
MT
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 128 M 6 174 M 6 174 M
Net income 2022 1 055 M 1 062 M 1 062 M
Net cash 2022 339 M 342 M 342 M
P/E ratio 2022 38,9x
Yield 2022 0,60%
Capitalization 41 012 M 41 313 M 41 313 M
EV / Sales 2022 6,64x
EV / Sales 2023 5,91x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 552,80 CHF
Average target price 800,68 CHF
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-27.42%41 313
MODERNA, INC.-43.98%56 593
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002
ALNYLAM PHARMACEUTICALS, INC.-26.37%15 622